Top

Journal of Endocrinological Investigation

Published in:

01-09-2019 | Insulins | Original Article

Decrease of FGF19 contributes to the increase of fasting glucose in human in an insulin-independent manner

Authors: J. Zhang, H. Li, N. Bai, Y. Xu, Q. Song, L. Zhang, G. Wu, S. Chen, X. Hou, C. Wang, L. Wei, A. Xu, Q. Fang, W. Jia

Published in: Journal of Endocrinological Investigation | Issue 9/2019

Abstract

Purpose

The ileum-derived fibroblast growth factor 19 (FGF19) plays key roles in hepatic glucose homeostasis in animals in an insulin-independent manner. Here, we analyzed the association of FGF19 with glucose effectiveness (GE, the insulin-independent glucose regulation), as well as hepatic glucose production (HGP) in Chinese subjects.

Methods

GE was measured by frequently sampled intravenous glucose tolerance test (FSIVGTT) in normal glucose tolerance (NGT), isolated-impaired glucose tolerance (I-IGT), and isolated-impaired fasting glucose (I-IFG) subjects. The oral glucose tolerance test-derived surrogate of GE (oGE) was determined in NGT, I-IFG, combined glucose intolerance (CGI), and type 2 diabetes (T2DM) subjects. HGP was assessed by labeled ([3-³H]-glucose) hyperinsulinemic–euglycemic clamp in NGT subjects. Insulin secretion and sensitivity were calculated by the hyperglycemic and hyperinsulinemic-euglycemic clamps in a subgroup of NGT, I-IGT, and I-IFG subjects. Serum FGF19 levels were determined by ELISA.

Results

FGF19 positively correlated with GE (r = 0.29, P = 0.004) as determined by FSIVGTT. The result was further confirmed by oGE (r = 0.261, P < 0.001). FGF19 was negatively associated with FPG (r = − 0.228, P = 0.025), but the association no longer existed after adjusting for GE (r = − 0.177, P = 0.086). FGF19 was negatively associated with basal HGP (r = − 0.697, P = 0.006). However, the correlation between FGF19 and insulin secretion and sensitivity were not found.

Conclusions

FGF19 levels are associated positively with GE and negatively with HGP. The increase of FPG in human is at least partially due to the decrease of FGF19 in an insulin-independent manner.

Available only for authorised users

Best JD, Kahn SE, Ader M, Watanabe RM, Ni TC, Bergman RN (1996) Role of glucose effectiveness in the determination of glucose tolerance. Diabetes Care 19:1018–1030CrossRefPubMed

Tonelli J, Kishore P, Lee DE, Hawkins M (2005) The regulation of glucose effectiveness: how glucose modulates its own production. Curr Opin Clin Nutr Metab Care 8:450–456CrossRefPubMed

Lorenzo C, Wagenknecht LE, Rewers MJ, Karter AJ, Bergman RN, Hanley AJ, Haffner SM (2010) Disposition index, glucose effectiveness, and conversion to type 2 diabetes: the insulin resistance atherosclerosis study (IRAS). Diabetes Care 33:2098–2103CrossRefPubMedPubMedCentral

Lorenzo C, Wagenknecht LE, Karter AJ, Hanley AJ, Rewers MJ, Haffner SM (2011) Cross-sectional and longitudinal changes of glucose effectiveness in relation to glucose tolerance: the insulin resistance atherosclerosis study. Diabetes Care 34:1959–1964CrossRefPubMedPubMedCentral

Osei K, Rhinesmith S, Gaillard T, Schuster D (2004) Impaired insulin sensitivity, insulin secretion, and glucose effectiveness predict future development of impaired glucose tolerance and type 2 diabetes in pre-diabetic African Americans: implications for primary diabetes prevention. Diabetes Care 27:1439–1446CrossRefPubMed

D’Alessio DA, Kahn SE, Leusner CR, Ensinck JW (1994) Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Investig 93:2263–2266CrossRefPubMed

Itoh N, Ornitz DM (2004) Evolution of the Fgf and Fgfr gene families. Trends Genet 20:563–569CrossRefPubMed

Itoh N (2010) Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease. Cell Tissue Res 342:1–11CrossRefPubMedPubMedCentral

Fukumoto S (2008) Actions and mode of actions of FGF19 subfamily members. Endocr J 55:23–31CrossRefPubMed

10.

Potthoff MJ, Kliewer SA, Mangelsdorf DJ (2012) Endocrine fibroblast growth factors 15/19 and 21: from feast to famine. Genes Dev 26:312–324CrossRefPubMedPubMedCentral

11.

Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, Sandusky GE, Hammond LJ, Moyers JS, Owens RA et al (2005) FGF-21 as a novel metabolic regulator. J Clin Investig 115:1627–1635CrossRefPubMed

12.

Jones S (2008) Mini-review: endocrine actions of fibroblast growth factor 19. Mol Pharm 5:42–48CrossRefPubMed

13.

Tomlinson E, Fu L, John L, Hultgren B, Huang X, Renz M, Stephan JP, Tsai SP, Powell-Braxton L, French D, Stewart TA (2002) Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 143:1741–1747CrossRefPubMed

14.

Fu L, John LM, Adams SH, Yu XX, Tomlinson E, Renz M, Williams PM, Soriano R, Corpuz R, Moffat B et al (2004) Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 145:2594–2603CrossRefPubMed

15.

Marcelin G, Jo YH, Li X, Schwartz GJ, Zhang Y, Dun NJ, Lyu RM, Blouet C, Chang JK, Chua S Jr (2014) Central action of FGF19 reduces hypothalamic AGRP/NPY neuron activity and improves glucose metabolism. Mol Metab 3:19–28CrossRefPubMed

16.

Kir S, Beddow SA, Samuel VT, Miller P, Previs SF, Suino-Powell K, Xu HE, Shulman GI, Kliewer SA, Mangelsdorf DJ (2011) FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 331:1621–1624CrossRefPubMedPubMedCentral

17.

Fang Q, Li H, Song Q, Yang W, Hou X, Ma X, Lu J, Xu A, Jia W (2013) Serum fibroblast growth factor 19 levels are decreased in Chinese subjects with impaired fasting glucose and inversely associated with fasting plasma glucose levels. Diabetes Care 36:2810–2814CrossRefPubMedPubMedCentral

18.

Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2003) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26(Suppl 1):S5–S20

19.

Hanefeld M, Koehler C, Fuecker K, Henkel E, Schaper F, Temelkova-Kurktschiev T (2003) Insulin secretion and insulin sensitivity pattern is different in isolated impaired glucose tolerance and impaired fasting glucose: the risk factor in impaired glucose tolerance for atherosclerosis and diabetes study. Diabetes Care 26:868–874CrossRefPubMed

20.

Meyer C, Pimenta W, Woerle HJ, Van Haeften T, Szoke E, Mitrakou A, Gerich J (2006) Different mechanisms for impaired fasting glucose and impaired postprandial glucose tolerance in humans. Diabetes Care 29:1909–1914CrossRefPubMed

21.

Zhang J, Li H, Zhou H, Fang L, Xu J, Yan H, Chen S, Song Q, Zhang Y, Xu A et al (2017) Lowered fasting chenodeoxycholic acid correlated with the decrease of fibroblast growth factor 19 in Chinese subjects with impaired fasting glucose. Sci Rep 7:6042CrossRefPubMedPubMedCentral

22.

Jia W, Chen L, Xiang K, Lu J, Bao Y, Xue F, Lu W (2001) Establishment of an extended hyperinsulinemic euglycemic clamp technique. Chin J Endocrinol Metab 17:268–271

23.

Pacini G, Tonolo G, Sambataro M, Maioli M, Ciccarese M, Brocco E, Avogaro A, Nosadini R (1998) Insulin sensitivity and glucose effectiveness: minimal model analysis of regular and insulin-modified FSIGT. Am J Physiol 274:E592–E599PubMed

24.

Steil GM, Volund A, Kahn SE, Bergman RN (1993) Reduced sample number for calculation of insulin sensitivity and glucose effectiveness from the minimal model. Suitability for use in population studies. Diabetes 42:250–256CrossRefPubMed

25.

Morbiducci U, Di Benedetto G, Kautzky-Willer A, Pacini G, Tura A (2007) Improved usability of the minimal model of insulin sensitivity based on an automated approach and genetic algorithms for parameter estimation. Clin Sci (Lond) 112:257–263CrossRef

26.

Morton GJ, Matsen ME, Bracy DP, Meek TH, Nguyen HT, Stefanovski D, Bergman RN, Wasserman DH, Schwartz MW (2013) FGF19 action in the brain induces insulin-independent glucose lowering. J Clin Invest 123:4799–4808CrossRefPubMedPubMedCentral

27.

Nagasaka S, Kusaka I, Yamashita K, Funase Y, Yamauchi K, Katakura M, Ishibashi S, Aizawa T (2012) Index of glucose effectiveness derived from oral glucose tolerance test. Acta Diabetol 49(Suppl 1):S195–S204CrossRefPubMed

28.

Jia W, Wu H, Bao Y, Wang C, Lu J, Zhu J, Xiang K (2007) Association of serum retinol-binding protein 4 and visceral adiposity in Chinese subjects with and without type 2 diabetes. J Clin Endocrinol Metab 92:3224–3229CrossRefPubMed

29.

Li H, Bao Y, Xu A, Pan X, Lu J, Wu H, Lu H, Xiang K, Jia W (2009) Serum fibroblast growth factor 21 is associated with adverse lipid profiles and gamma-glutamyltransferase but not insulin sensitivity in Chinese subjects. J Clin Endocrinol Metab 94:2151–2156CrossRefPubMed

30.

DeFronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214–E223

31.

DeFronzo RA, Gunnarsson R, Bjorkman O, Olsson M, Wahren J (1985) Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus. J Clin Investig 76:149–155CrossRefPubMed

32.

Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22:1462–1470CrossRefPubMed

33.

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419CrossRef

34.

Potthoff MJ, Boney-Montoya J, Choi M, He T, Sunny NE, Satapati S, Suino-Powell K, Xu HE, Gerard RD, Finck BN et al (2011) FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1alpha pathway. Cell Metab 13:729–738CrossRefPubMedPubMedCentral

35.

Egede MB, Henriksen JE, Durck TT, Levin K, Rantzau C, Ward G, Beck-Nielsen H, Alford FP (2014) Glucose effectiveness in nondiabetic relatives: dysglycemia and beta-cell function at 10 years. J Clin Endocrinol Metab 99:1420–1424CrossRefPubMed

36.

Bergman RN (1989) Lilly lecture 1989. Toward physiological understanding of glucose tolerance. Minimal-model approach. Diabetes 1989(38):1512–1527CrossRef

37.

Ryan KK, Kohli R, Gutierrez-Aguilar R, Gaitonde SG, Woods SC, Seeley RJ (2013) Fibroblast growth factor-19 action in the brain reduces food intake and body weight and improves glucose tolerance in male rats. Endocrinology 154:9–15CrossRefPubMed

38.

Kurosu H, Choi M, Ogawa Y, Dickson AS, Goetz R, Eliseenkova AV, Mohammadi M, Rosenblatt KP, Kliewer SA, Kuro-o M (2007) Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem 282:26687–26695CrossRefPubMedPubMedCentral

39.

Lin BC, Wang M, Blackmore C, Desnoyers LR (2007) Liver-specific activities of FGF19 require Klotho beta. J Biol Chem 282:27277–27284CrossRefPubMed

40.

DeFronzo RA, Bonadonna RC, Ferrannini E (1992) Pathogenesis of NIDDM. A balanced overview. Diabetes Care 15:318–368CrossRefPubMed

41.

Ader M, Ni TC, Bergman RN (1997) Glucose effectiveness assessed under dynamic and steady state conditions Comparability of uptake versus production components. J Clin Investig 99:1187–1199CrossRefPubMed

Title: Decrease of FGF19 contributes to the increase of fasting glucose in human in an insulin-independent manner
Authors: J. Zhang
H. Li
N. Bai
Y. Xu
Q. Song
L. Zhang
G. Wu
S. Chen
X. Hou
C. Wang
L. Wei
A. Xu
Q. Fang
W. Jia
Publication date: 01-09-2019
Publisher: Springer International Publishing
Keywords: Insulins
Insulins
Published in: Journal of Endocrinological Investigation / Issue 9/2019
Electronic ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-019-01018-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 9/2019

Liraglutide increases bone formation and inhibits bone resorption in rats with glucocorticoid-induced osteoporosis

Changes in left ventricular repolarization after short-term testosterone replacement therapy in hypogonadal males

Reliability of calcium–phosphorus (Ca/P) ratio as a new, accurate and inexpensive tool in the diagnosis of some Ca–P disorders

Vitamin D status and non-alcoholic fatty liver disease in patients with type 1 diabetes

Comparative assessment of hypothalamic-pituitary-adrenal axis suppression secondary to intrabursal injection of different glucocorticoids: a pilot study

The resting metabolic rate in women with polycystic ovary syndrome and its relation to the hormonal milieu, insulin metabolism, and body fat distribution: a cohort study

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials